Angina Pectoris Drugs Market Size, Share, Competitive Landscape and Trend Analysis Report
Angina Pectoris Drugs Global Market Report 2025
The Business Research Company's Angina Pectoris Drugs Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, November 24, 2025 /EINPresswire.com/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors
How Large Will The Angina Pectoris Drugs Market Be By 2025?
The market size for angina pectoris drugs has seen a constant increase over the past years. It is expected to rise from $12.32 billion in 2024 to $12.88 billion in 2025, with a 4.5% compound annual growth rate (CAGR). The historical growth is due to a high occurrence of heart diseases, an aging population, lifestyle related factors, a rise in hypertension rates, and the preponderance of diabetes.
In the ensuing years, a substantial growth is projected for the angina pectoris drugs market. The market is set to escalate to ""$16.42 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.3%. The forecasted growth is associated with the increasing global obesity rates, development in precision medicine, emphasis on preventive cardiology, patient awareness programs, and studies on new potential therapeutic targets. Key market trends during this period contain telemedicine for remote patient monitoring, tangible evidence and outcome research, patient-focused medication education, strategic partnerships for market entry, advancements in regulation, and quickened approvals.
Download a free sample of the angina pectoris drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10797&type=smp
What Are The Major Driving Forces Influencing The Angina Pectoris Drugs Market Landscape?
The growth of the angina pectoris drug market is anticipated to be driven by the rising incidence of cardiovascular diseases. These encompass a variety of disorders affecting the heart and blood vessels, such as coronary artery disease, elevated blood pressure, heart failure, and stroke. Several factors contribute to the growing incidence of cardiovascular diseases (CVD), including an ageing demographic, unhealthy living habits, and the obesity crisis. Medicines for angina pectoris like nitrates, beta-blockers, and calcium channel blockers provide effective relief from chest pain and discomfort due to inadequate blood supply to the heart, thereby improving patients' overall quality of life. For example, data released by the British Heart Foundation, a UK-based cardiovascular research charity, disclosed that about 7.6 million people in the UK are afflicted by heart and circulatory diseases, with roughly 4 million males and 3.6 million females dealing with these conditions. These diseases account for roughly 27% of all UK deaths, leading to over 170,000 deaths per year, or about 480 deaths per day, which means one death every three minutes. As a result, the escalating incidence of cardiovascular diseases is fuelling the angina pectoris drug market's growth.
Who Are The Top Players In The Angina Pectoris Drugs Market?
Major players in the Angina Pectoris Drugs include:
• Astellas Pharma Inc.
• Bayer AG
• Novartis AG
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Merck & Co Inc.
• Eli Lilly and Company
• Pfizer Inc.
• Abbott Laboratories
• Sun Pharmaceutical Industries Limited
What Are The Key Trends Shaping The Angina Pectoris Drugs Industry?
The emergence of product innovation is a prominent trend in the market for angina pectoris drugs. To maintain their market share, leading companies are embracing new technologies. For example, in March 2023, Hikma Pharmaceuticals PLC, a pharmaceutical corporation based in the UK, introduced Labetalol Hydrochloride Injection, USP, in a ready-to-use syringe. This product has received approval from the Food and Drug Administration of the United States. In hospital settings, the 10 mg/2 mL PFS dosage is utilised for treating severe hypertension and reducing blood pressure.
Market Share And Forecast By Segment In The Global Angina Pectoris Drugs Market
The angina pectoris drugs market covered in this report is segmented –
1) By Drugs: Nitrates, Antiplatelet Agents, Beta-adrenergic Blocking Agents, Calcium Channel Blockers, Anti-ischemic Agents, Statins, Antihypertensive Agents, Other Drugs
2) By Indication: Stable Angina, Unstable Angina, Prinzmetal’s Angina
3) By Route of Administration: Oral, Parenteral, Transdermal, Other Route Of Administrations
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Nitrates: Short-Acting Nitrates, Long-Acting Nitrates
2) By Antiplatelet Agents: Aspirin, Clopidogrel
3) By Beta-Adrenergic Blocking Agents: Non-Selective Beta Blockers, Selective Beta Blockers
4) By Calcium Channel Blockers: Dihydropyridine Calcium Channel Blockers, Non-dihydropyridine Calcium Channel Blockers
5) By Anti-Ischemic Agents: Ranolazine, Ivabradine
6) By Statins: Atorvastatin, Rosuvastatin
View the full angina pectoris drugs market report:
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Angina Pectoris Drugs Market Regional Insights
In 2024, North America dominated the market for angina pectoris drugs. However, Asia-Pacific is anticipated to experience the quickest growth during the forecast period. The report provides insights into several regions, including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
Browse Through More Reports Similar to the Global Angina Pectoris Drugs Market 2025, By The Business Research Company
Muscle Relaxant Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report
Alzheimers Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Osteoporosis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/osteoporosis-drugs-global-market-report
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"
Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
